AllianceBernstein’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-1,244,815
Closed -$4.73M 3313
2020
Q1
$4.73M Buy
1,244,815
+674,813
+118% +$2.91M ﹤0.01% 1212
2019
Q4
$2.9M Buy
570,002
+450,500
+377% +$2.38M ﹤0.01% 1755
2019
Q3
$604K Sell
119,502
-18,950
-14% -$94.5K ﹤0.01% 2470
2019
Q2
$854K Buy
138,452
+42,500
+44% +$205K ﹤0.01% 2381
2019
Q1
$445K Buy
95,952
+14,600
+18% +$66.1K ﹤0.01% 2565
2018
Q4
$342K Hold
81,352
﹤0.01% 2662
2018
Q3
$510K Hold
81,352
﹤0.01% 2609
2018
Q2
$654K Sell
81,352
-13,300
-14% -$102K ﹤0.01% 2515
2018
Q1
$706K Hold
94,652
﹤0.01% 2409
2017
Q4
$563K Hold
94,652
﹤0.01% 2495
2017
Q3
$697K Hold
94,652
﹤0.01% 2457
2017
Q2
$643K Sell
94,652
-145,780
-61% -$1.08M ﹤0.01% 2510
2017
Q1
$2.27M Sell
240,432
-213,410
-47% -$2.13M ﹤0.01% 1724
2016
Q4
$3.92M Buy
453,842
+344,890
+317% +$2.55M ﹤0.01% 1350
2016
Q3
$690K Hold
108,952
﹤0.01% 2388
2016
Q2
$460K Sell
108,952
-35,700
-25% -$172K ﹤0.01% 2547
2016
Q1
$631K Buy
144,652
+42,170
+41% +$188K ﹤0.01% 2329
2015
Q4
$628K Buy
102,482
+730
+0.7% +$4.79K ﹤0.01% 2358
2015
Q3
$582K Hold
101,752
﹤0.01% 2431
2015
Q2
$759K Buy
101,752
+10,700
+12% +$64.7K ﹤0.01% 2421
2015
Q1
$544K Hold
91,052
﹤0.01% 2456
2014
Q4
$688K Hold
91,052
﹤0.01% 2386
2014
Q3
$473K Hold
91,052
﹤0.01% 2525
2014
Q2
$392K Buy
91,052
+34,529
+61% +$132K ﹤0.01% 2588
2014
Q1
$231K Buy
56,523
+10,700
+23% +$54.7K ﹤0.01% 2715
2013
Q4
$244K Sell
45,823
-10,300
-18% -$45.3K ﹤0.01% 2740
2013
Q3
$282K Sell
56,123
-10,304
-16% -$55.9K ﹤0.01% 2751
2013
Q2
$296K Buy
+66,427
New +$298K ﹤0.01% 2719

Other funds holding PGNX

AllianceBernstein's PGNX Position: Q2 2020 in Review

AllianceBernstein sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 1,244,815 shares — an estimated $4.73M sold.

AllianceBernstein first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $4.73M in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • AllianceBernstein reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • AllianceBernstein sold 1,244,815 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $4.73M.
  • AllianceBernstein first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • AllianceBernstein's Progenics Pharmaceuticals Inc position peaked at $4.73M in Q1 2020.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on AllianceBernstein's 13F filing for Q2 2020, filed 13 Aug 2020.